Article
Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Antimicrobial agents and chemotherapy - 1 Nov 2005
Hazen Richard J, Harvey Robert J, St Clair Marty H, Ferris Robert G, Freeman George A, Tidwell Jeffrey H, Schaller Lee T, Cowan Jill R, Short Steven A, Romines Karen R, Chan Joseph H, Boone Lawrence R
Abstract excerpt
GW678248, a novel nonnucleoside reverse transcriptase inhibitor, has been evaluated for anti-human immunodeficiency virus activity in a variety of in vitro assays against laboratory strains and clinical isolates. When GW678248 was tested in combination with approved drugs in the nucleoside and nucleotide reverse transcriptase inhibitor classes or the protease inhibitor class, the antiviral activities were either...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.